open access

Vol 16, No 3 (2020)
Guidelines / Expert consensus
Published online: 2020-07-08
Get Citation

Supportive care. Neutropenia

Piotr Potemski, Rafał Czyżykowski
Oncol Clin Pract 2020;16(3):87-96.

open access

Vol 16, No 3 (2020)
GUIDELINES FOR DIAGNOSTIC AND THERAPEUTIC MANAGEMENT
Published online: 2020-07-08

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Supportive care. Neutropenia

Journal

Oncology in Clinical Practice

Issue

Vol 16, No 3 (2020)

Article type

Guidelines / Expert consensus

Pages

87-96

Published online

2020-07-08

Bibliographic record

Oncol Clin Pract 2020;16(3):87-96.

Authors

Piotr Potemski
Rafał Czyżykowski

References (18)
  1. Common Terminology Criteria for Adverse Events (Version 5.0). Dostęp on-line: 10.01.2020 (https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf).
  2. Klastersky J, de Na, Rolston K, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016; 27(supl. 5): v111–v118.
  3. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious Diseases Society of America. Clin Infect Dis. 2011; 52(4): e56–e93.
  4. NCCN Guidelines Version 1.2020. Prevention and treatment of cancer-related infections. Dostęp on-line: 10.01.2020.
  5. Crawford J, Caserta C, Roila F, et al. ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol. 2010; 21 Suppl 5: v248–v251.
  6. Kamana M, Escalante C, Mullen CA, et al. Bacterial infections in low-risk, febrile neutropenic patients. Cancer. 2005; 104(2): 422–426.
  7. Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007; 30 Suppl 1: S51–S59.
  8. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000; 18(16): 3038–3051.
  9. Feld R. Bloodstream infections in cancer patients with febrile neutropenia. Int J Antimicrob Agents. 2008; 32 Suppl 1: S30–S33.
  10. Singer M, Deutschman C, Seymour C, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8): 801.
  11. Raad I, Hanna HA, Alakech B, et al. Differential time to positivity: a useful method for diagnosing catheter-related bloodstream infections. Ann Intern Med. 2004; 140(1): 18–25.
  12. Mhaskar R, Clark OA, Lyman G, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev. 2014(10): CD003039.
  13. NCCN Clinical Practice Guidelines in Oncology. Hematopoietic growth factors. Dostęp on-line: 15.11.2019.
  14. Smith TJ, Bohlke K, Lyman GH, et al. American Society of Clinical Oncology. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015; 33(28): 3199–3212.
  15. Sung L, Nathan PC, Alibhai SMH, et al. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med. 2007; 147(6): 400–411.
  16. Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010; 28(17): 2914–2924.
  17. Lyman GH, Dale DC, Culakova E, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2013; 24(10): 2475–2484.
  18. Aapro MS, Bohlius J, Cameron DA, et al. European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011; 47(1): 8–32.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl